Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 1, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
加利福尼亞州門洛帕克，2024年4月24日（GLOBE NEWSWIRE）——Corcept Therapeutics Incorporated（納斯達克股票代碼：CORT）今天宣佈將在2024年5月1日公佈第一季度財務業績並提供公司最新情況。該公司還將在當天美國東部時間下午 5:00（太平洋時間下午 2:00）舉行電話會議。
Conference Call Information
電話會議信息
Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller.
參與者必須在電話會議之前單擊此處進行註冊。註冊後，每位參與者將收到一個撥入號碼和一個唯一的訪問密碼。每個接入 PIN 可容納一名來電者。
Additionally, a listen-only webcast will be available by clicking here.
此外，單擊此處將提供僅限收聽的網絡直播。
A replay of the call will be available on the Investors / Events tab of .
電話會議的重播將在的 “投資者/活動” 選項卡上提供。
About Corcept Therapeutics
關於 Corcept Therap
For over 25 years, Corcept's focus on cortisol modulation and its potential to treat patients across a wide variety of serious disorders has led to the discovery of more than 1,000 proprietary selective cortisol modulators. Corcept's advanced clinical trials are being conducted in patients with hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS) and non-alcoholic steatohepatitis (NASH). In February 2012, the company introduced Korlym, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing's syndrome. Corcept is headquartered in Menlo Park, California. For more information, visit .
25年來，Corcept專注於皮質醇調節及其治療各種嚴重疾病患者的潛力，這促使人們發現了1,000多種專有的選擇性皮質醇調節劑。Corcept的高級臨床試驗正在對皮質醇增多、實體瘤、肌萎縮性側索硬化（ALS）和非酒精性脂肪性肝炎（NASH）患者進行。2012年2月，該公司推出了Korlym，這是美國食品藥品監督管理局批准的第一種用於治療庫欣綜合徵患者的藥物。Corcept總部位於加利福尼亞州的門洛帕克。欲了解更多信息，請訪問。
CONTACT:
Investor inquiries:
ir@corcept.com
Media inquiries:
communications@corcept.com
聯繫人：
投資者查詢：
ir@corcept.com
媒體查詢：
communications@corcept.com